Showing 201 - 210 of 36,279
Objectives: To measure preferences and willingness to pay (WTP) for a novel anaesthetic (dental gel) versus existing anaesthetic options for periodontal maintenance visits. Design: The study was conducted by developing and administering a survey, composed of a modified decision aid and a WTP...
Persistent link: https://www.econbiz.de/10005243206
Background: Although several studies have determined quality of life in patients with lung cancer, there is still little information about the use of generic questionnaires [e.g. the 36-item Short Form health survey (SF-36)] and utility questionnaires [e.g. the EuroQOL instrument (EQ-5D)] in...
Persistent link: https://www.econbiz.de/10005243207
Pharmacoeconomics is vitally important to drug manufacturers in terms of communicating to external decision-makers (payers, prescribers, patients) the value of their products, achieving regulatory and reimbursement approval and contributing to commercial success. Since development of new drugs...
Persistent link: https://www.econbiz.de/10005243209
Objective: To estimate the economic value of pharmacological treatment of type 2 diabetes mellitus in overweight and obese patients using orlistat in addition to standard diabetes therapy (i.e., a sulphonlyurea, metformin or insulin) and weight management strategies as compared with standard...
Persistent link: https://www.econbiz.de/10005243210
Coronary heart disease (CHD) is a major cause of death and illness in industrialised countries. Like other hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, pravastatin reduces total and low density lipoprotein (LDL)-cholesterol levels and increases high density lipoprotein...
Persistent link: https://www.econbiz.de/10005243215
The incidence, morbidity and mortality of chronic obstructive pulmonary disease (COPD) is rising throughout the world. The total economic cost of COPD in the US in 1993 was estimated to be over $US15.5 billion, with $US6.1 billion for hospitalisation, $US4.4 billion for physician and other fees,...
Persistent link: https://www.econbiz.de/10005243216
The current divisions in managing prescribing between primary and secondary care in the UK arise from separate budgetary arrangements. These divisions are neither sensible, organisationally efficient nor cost effective. Transition of patients across the interface of primary and secondary care...
Persistent link: https://www.econbiz.de/10005243217
Persistent link: https://www.econbiz.de/10005243218
In pharmacoeconomic research sponsored by companies, there is an obvious tension between the desire to undertake studies to show a marketing advantage and the desire to adhere to good scientific principles. This tension was explored in an early issue of PharmacoEconomics and is now revisited 5...
Persistent link: https://www.econbiz.de/10005243219
Background:Background: The benefit of unfractionated heparin (UFH) added to aspirin in patients with acute coronary syndromes (ACS) was described more than 20 years ago. Ever since, a wide variety of anticoagulant drugs have become available for clinical use, including low-molecular-weight...
Persistent link: https://www.econbiz.de/10009653278